Medicare Policy at the Crossroads: Addressing Artificial Intelligence and Software
AdvaMed® collaborated with CapView Strategies to develop this new report on improving coverage and payment for AI/software in Medicare. This work builds on the analysis and recommendations from an earlier collaboration. As described in the first report, CMS has the regulatory flexibility to incorporate digital health technologies—including AI/software innovations—into its payment pathways as the statutory parameters for Medicare’s benefit categories accommodate evidence-based, digital health solutions. This second report updates the previous analysis with a specific focus on AI/software.
Related Reading
News / AdvaMed Advancements / Artificial Intelligence (AI) / Coverage & Payment / Diabetes / Diagnostics / Digital Health / Global & Trade / Health Access / Investor Relations / Medical Imaging / Orthopedic / Regulatory Affairs / Tariffs / The MedTech Conference / Value-Based Collaborations
AdvaMed Concludes Record-Breaking MedTech Conference 2026
October 28, 2026
BOSTON—AdvaMed, the Medtech Association, concluded The MedTech Conference 2026, convening more than 4,470 attendees from 2,050 companies from 40 countries for the global medtech industry’s premier annual gathering.
News / Artificial Intelligence (AI) / Regulatory Affairs
AdvaMed Encourages Risk-Based FDA Approach to Generative AI Medical Devices
October 27, 2026
WASHINGTON—AdvaMed, the Medtech Association, encouraged the U.S. Food and Drug Administration (FDA) to build on its existing regulatory framework for generative AI (GenAI)-enabled medical devices rather than create new frameworks that could impede the innovations serving patients. The comments respond to FDA’s discussion paper (Docket No. FDA-2026-N-7874) seeking early input on assessing risks and evaluating GenAI devices before marketing and post-market monitoring.
News / Artificial Intelligence (AI) / Health Access
Paradromics Demonstrates Four Years of Stable Neural Recording in Major Brain-Computer Interface Durability Milestone
October 8, 2026
AUSTIN, Texas – October 8, 2026 – Paradromics Inc., a neurotechnology company developing high-data-rate brain-computer interfaces (BCIs) to restore and enhance human capabilities, today announced that its brain-computer interface has demonstrated more than four years of stable neural recording and decoding performance.
Resource / Artificial Intelligence (AI)
MedTech 2026 Trends: Engineering Outcomes, Intelligence and Trust
October 2, 2026
Explore the engineering, technology and compliance shifts shaping medtech in 2026, from patient-centric innovation to evolving global frameworks.
Resource / Artificial Intelligence (AI)
Physical AI in MedTech: Why the Hard Questions Matter more than the Hype
October 1, 2026
Explore how Physical AI is transforming medtech and the key challenges around trust, regulation, integration and collaboration that will shape its future.
Blog / Artificial Intelligence (AI) / Digital Health / The MedTech Conference
AdvaMed® in Action: A New Chapter for Digital Health Tech at #MTC26
September 15, 2026
Kirsten Tullia shares how AdvaMed Digital Health Tech priorities—from AI and cybersecurity to payment and data—will come to life at #MTC26 in Boston.
News / Coverage & Payment / Health Access / Regulatory Affairs
AdvaMed Welcomes Expiration of Moratorium on New Medicare Durable Medical Equipment Suppliers
August 27, 2026
WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, today welcomed the expiration of the moratorium on Medicare acceptance of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) suppliers. He made the following comment on the expiration.
Blog / Artificial Intelligence (AI) / Digital Health / Health Access
The Insight Series: AI & Digital Health with Kelly Huang
August 27, 2026
“The Insight Series: AI & Digital Health” features industry experts answering key questions to help inform policymakers and the public about how AI is shaping the future of care delivery. This edition features Kelly Huang, CEO of Elucid, an AI medical technology company focused on providing physicians with a more precise, non-invasive view of atherosclerosis to drive patient-specific cardiovascular care.